KURA ONCOLOGY, INC. Cash and Restricted Cash
KURA ONCOLOGY, INC. (KURA) had Cash and Restricted Cash of $70.24 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $70.24M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $39.08M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $149.10M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $95.29M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $70.24M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $39.08M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $149.10M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $95.29M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $81.95M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $51.27M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $224.46M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $49.48M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $45.18M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $41.51M 10-Q · filed 2025-05-01 | |
| 2023-12-31 | $37.32M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $28.74M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $49.12M 10-Q · filed 2024-08-08 | $49.33M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $27.06M 10-Q · filed 2024-05-02 | $27.27M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $51.80M 10-K · filed 2026-03-05 | $52.01M 10-K · filed 2023-02-23 |
| 2022-09-30 | $90.94M 10-Q · filed 2023-11-02 | $91.15M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $39.47M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $34.04M 10-Q · filed 2023-05-10 | |
| 2021-12-31 | $90.67M 10-K · filed 2025-02-28 | $90.88M 10-K · filed 2022-02-24 |
| 2021-09-30 | $39.39M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $39.18M 10-Q · filed 2022-08-03 | |
| 2021-03-31 | $111.05M 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $325.49M 10-K · filed 2024-02-27 | $325.70M 10-K · filed 2021-02-24 |
| 2020-09-30 | $77.17M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $134.97M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $34.02M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $26.14M 10-K · filed 2023-02-23 | |
| 2019-09-30 | $54.74M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $122.08M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $17.78M 10-Q · filed 2020-05-04 | |
| 2018-12-31 | $16.12M 10-K · filed 2022-02-24 | |
| 2018-09-30 | $20.57M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $11.43M 10-K · filed 2021-02-24 | |
| 2016-12-31 | $9.72M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |